Experts believe that the three newer classes of antidiabetic agents, namely, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, should better demonstrate cardiovascular safety in addition to glycemic efficacy, but some of the SGLT2 inhibitors and GLP-1 receptor agonists have not only demonstrated non-inferiority but also superiority in clinical trials of cardiovascular outcomes, exhibiting promising prospects for the diabetes community. This evidence concerns the gene GLP1R and diabetes mellitus.